Fellow Health Taps Fertility Veteran Paul Kappelman to Lead Board

SAN LEANDRO, CA – February 18, 2026 – In a strategic move signaling a new phase of aggressive growth, male reproductive health company Fellow Health has appointed seasoned healthcare executive Paul Kappelman as its new Independent Chairman of the Board. The appointment brings a leader with over three decades of experience, particularly in scaling fertility care organizations, to the helm of a company aiming to revolutionize a long-overlooked aspect of reproductive medicine.

Fellow Health, which has gained significant traction since its 2018 founding, focuses on patient-centric, mail-in testing solutions. The addition of Kappelman, a former fertility network CEO and current private equity advisor, is set to provide invaluable guidance as the company expands its clinical partnerships and solidifies its position in the burgeoning health-tech landscape.

“Paul has unmatched experience building and scaling healthcare organizations,” said Brian Hogan, CEO of Fellow Health. “As we continue to grow our network of more than 3,000 fertility and urology practices, his perspective as a former fertility CEO and board leader will be invaluable. We’re excited to welcome Paul as Chairman as we focus on scaling with intention, strengthening clinical partnerships, and expanding access to modern reproductive health solutions for men.”

A Proven Leader for a Scaling Innovator

Paul Kappelman’s resume reads like a blueprint for healthcare growth and consolidation. His most recent high-profile role was as CEO of Ovation Fertility, a prominent network of IVF and genetics laboratories. During his tenure, he not only strengthened clinical operations but also steered the company through its successful acquisition by US Fertility in 2023, a move that created one of the nation's largest and most comprehensive fertility networks.

His expertise extends beyond the fertility lab. Kappelman has a deep history in hospital system leadership, having served as Chief Operating Officer of Ardent Health Services and leading hospital operations at LHP Hospital Group. His experience even includes the ground-up development and launch of a new hospital. This broad operational acumen is complemented by his current role as a Senior Independent Operating Advisor to Morgan Stanley Capital Partners, where he guides healthcare management teams on growth strategy and governance. This background is particularly relevant given MSCP's history with Ovation Fertility, which it owned and successfully sold under Kappelman's leadership, demonstrating his ability to generate value within a private-equity-backed framework.

For Fellow Health, a company that recently secured a $24 million Series B funding round and projects over 40% year-over-year revenue growth, Kappelman’s appointment is a clear indicator of its ambitions. His experience in managing mergers, developing joint venture partnerships, and scaling operational platforms will be critical as the company navigates its next chapter.

Redefining Diagnostics with Clinical Rigor

The core of Fellow Health's disruption lies in its ability to solve a fundamental problem in male fertility: the inconvenience and discomfort of traditional, in-clinic semen analysis. For decades, the process has been a significant barrier for patients, contributing to a lack of comprehensive data when couples seek fertility care. Male factors are now understood to contribute to approximately 50% of infertility cases, yet the diagnostic process has remained stubbornly archaic.

Fellow Health addresses this with a mail-in kit that combines convenience with clinical validity. What sets the company apart from other at-home solutions is its investment in scientific validation. The company’s claim of being the only mail-in test with peer-reviewed data is substantiated by a 2021 study published in the prestigious journal Fertility and Sterility. The research, conducted in partnership with leading urologists, demonstrated that the company's proprietary preservation solution and methodology could accurately calculate a sample's initial quality even after 26 hours. The study found that while motility and morphology decreased over time, they did so at predictable linear rates, allowing for a reliable calculation of the baseline metrics. This validation gives clinicians the confidence to integrate the mail-in results into their patient care protocols.

“Fellow Health is addressing long-standing gaps in reproductive health by combining clinical rigor with a modern, patient-first model,” Kappelman stated. “The company has built meaningful trust with providers by making care easier to deliver and easier for patients to complete.”

This trust is reflected in the company’s scale. It currently partners with over 3,000 clinical practices, including 11 of the top 15 U.S. hospitals, and processes over 400 patient samples daily in its CLIA-certified lab. Since 2020, the company has delivered over 100,000 test results, marking a significant footprint in the diagnostics space.

Navigating the Evolving Fertility Landscape

Kappelman joins Fellow Health at a pivotal moment for the entire fertility industry. The market is rapidly evolving, driven by technological advancements and a growing awareness of the complexities of reproductive health. At-home diagnostics are gaining consumer and clinician acceptance, while artificial intelligence is beginning to revolutionize sperm selection and data analysis. Fellow Health is squarely at the center of these trends.

The company is not without competition. Health-tech giants like Ro, which acquired sperm storage company Dadi in 2022, and venture-backed clinics like Posterity Health are also vying for a share of the male fertility market. However, Fellow Health's focus on peer-reviewed clinical validation and its deep integration with existing urology and fertility practices provide a strong competitive moat.

The company’s model has also proven effective beyond initial fertility testing. Its post-vasectomy kits have shown an 82% compliance rate—a dramatic improvement over the low follow-up rates associated with traditional in-clinic testing. This demonstrates the power of its platform to solve compliance and access issues across different areas of male reproductive health.

Looking ahead, Fellow Health is exploring how seminal fluid can be used for future diagnostics, potentially as a non-invasive liquid biopsy for conditions like prostate cancer. The appointment of an experienced leader like Paul Kappelman is not just about scaling the current business; it is about building the infrastructure to support a long-term vision where male reproductive health is proactive, accessible, and integrated into mainstream healthcare. His leadership will be instrumental as the company works to not only expand its market share but also redefine the standard of care for an entire generation.